Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Clinical trial NCT01066468 · TERMINATED

Trial details

NCT number: NCT01066468
Sponsor: Novartis Pharmaceuticals
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Chronic Myeloid Leukemia (CML)Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)

Start date: 2010-10-01
Primary completion: 2011-05-01
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.